I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates

Company’s IPO in January 2020, with multiple important data readouts for lemzoparlimab (TJC4), uliledlimab (TJD5) and other clinical assets expected in 2021 New drug application (NDA) submission for …
( read original story …)

---